The July 2014 issue of the New Zealand Schedule of Pharmaceutical Benefits is now in effect. There are no listings of new medicines this month; there are two major new indications; etanercept (Enbrel) and adalimumab (Humira) for use by patients with pyoderma gangrenosum. Neither of these medicines have been registered by Medsafe for such use. It is unclear if and when these medicines were considered by PTAC.

For more details, go to: http://www.pharmac.govt.nz/2014/06/19/SU.pdf